Results 61 to 70 of about 6,539 (200)
The role of benralizumab in eosinophilic immune dysfunctions: a case report-based literature review [PDF]
, 2023 In the past years, the knowledge of eosinophils playing a primary pathophysiologic role in several associated conditions has led to the development of biologics targeting therapies aiming at normalizing the immune response, reducing chronic inflammation,
Branco, Joana +5 more
core +1 more source
Financial Toxicity Associated with Biological Medicines: A Scoping Review
Clinical Pharmacology &Therapeutics, EarlyView.Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka +4 more
wiley +1 more source
Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma
European Clinical Respiratory JournalBackground Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited.Methods This clinical study was a multicentre ...
Kohei Somekawa +19 more
doaj +1 more source
Inhalation therapy in the next decade : Determinants of adherence to treatment in asthma and COPD [PDF]
, 2018 Peer reviewedPublisher ...
Amaducci, Sandro +36 more
core +5 more sources
JPGN Reports, EarlyView.Abstract Crohn's disease (CD) and eosinophilic gastrointestinal diseases (EGIDs) are distinct inflammatory entities, but eosinophilic disease may emerge as a paradoxical immune complication of anti–tumor necrosis factor therapy. We report a 12‐year‐old boy with terminal ileal CD who developed severe eosinophilic gastritis and ileitis, peripheral ...
Jonathan Dudzik +3 more
wiley +1 more source
Respirology, EarlyView.ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley +1 more source
World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou +4 more
wiley +1 more source
Allergy, EarlyView.ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier +221 more
wiley +1 more source
Allergy, EarlyView.ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh +7 more
wiley +1 more source
Allergy, EarlyView.This meta‐analysis included 2292 patients with severe asthma who underwent biologic switching across 23 countries/regions. The most prevalent switching pattern was from mepolizumab to benralizumab, with suboptimal asthma control being the primary reason.
Yang Zheng +13 more
wiley +1 more source